Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

By afschroeder • February 1, 2026

Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim S, King J, Hines OJ, Girgis M, Sadeghi S, Olevsky O, Wong D, Yonemoto L, Siney AM, Kelly K, Kivork C, Tseng CH, Radu CG, Dawson DW, Donahue TR. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Nat Commun. 2026 Jan 31. doi: 10.1038/s41467-026-68976-2. Epub ahead of print. PMID: 41620440.

Tags: General Internal Medicine, Hematology/Oncology, Publications

Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers

Riemann S, Meulmeester FL, Mailhot-Larouche S, Ramakrishnan S, Wechsler ME, Corren J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Laugerud[...]

Rheumatoid arthritis in crisis: investigating the impact of stress on RA flares during the COVID-19 pandemic

Morris NT, Woodworth T, Pham A, Elashoff DA, Brook J, Furst DE, Ranganath VK. Rheumatoid arthritis in crisis: investigating the impact of stress on RA[...]

First Reported Case of Capnocytophaga cynodegmi Infective Endocarditis: A Diagnostic Odyssey

Tran LNB, Zhuo R, Singha M, Sekhon H, Yang S, Fishbein GA, Tymchuk C, Allyn PR. First Reported Case of Capnocytophaga cynodegmi Infective Endocarditis: A[...]